Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
9.99
-0.10 (-0.99%)
Dec 5, 2025, 4:00 PM EST - Market closed
Aligos Therapeutics Employees
Aligos Therapeutics had 70 employees as of December 31, 2024. The number of employees increased by 4 or 6.06% compared to the previous year.
Employees
70
Change (1Y)
4
Growth (1Y)
6.06%
Revenue / Employee
$37,800
Profits / Employee
-$1,235,171
Market Cap
61.47M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALGS News
- 15 days ago - Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Aligos Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference - GlobeNewsWire